NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Scienture Holdings, Inc. SCNX
13 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$431,609
▲ 215.9% vs FY2024
EPS · FY25
$-2.70
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-55.6%
Net margin · FY25
-9618.0%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 431,609.00
Revenue, FY2025 · full 13-year series below
Revenue
Net income
The company lost 9618 cents on every revenue dollar this year.
Per share
USD -2.70
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-55.6%
Return on equity, FY2025
ROE
Operating margin-9867.9%
Net margin-9618.0%
Return on assets-43.9%
Each USD of equity lost 56 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−52.1% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−65.2%
−52.1%
−17.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.04B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 84.2M
total assets, end of FY2025
Total assetsUSD 84.2M
EquityUSD 70.1M
CashUSD 6.7M
DepositsUSD 1.2M
Current ratio2.89×
Equity funds 83% of total assets.
History
13 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
·
0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
−0.0
−0.0
·
·
·
·
·
·
·
·
·
·
·
Net income $B
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−2.70
2.48
−23.35
−6.13
−0.65
−0.33
−0.05
0.00
0.01
−0.09
−0.04
−0.07
−0.15
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
164
·
·
·
·
·
·
·
·
·
·
·
ROE %
−55.6
22.8
−2733.6
−153.2
−85.4
−39.6
−11.4
3.4
·
·
−238.9
−503.4
−1598.0
Shares out B
0.04
0.01
0.00
0.00
0.01
0.01
0.01
0.01
0.03
0.03
0.03
0.03
0.03
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
50 of 50
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed